Nisa Investment Advisors
KLRS

Nisa Investment Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Nisa Investment Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Hold
0
– -$6 – 3065
2024
Q3 		– Hold
0
– – – 2957
2024
Q2 		– Hold
0
– – – 2934
2024
Q1 		– Sell
-31
Closed -$483 – 2823
2023
Q4 		$483 Sell
31
-3
-9% -$118 ﹤0.01% 2414
2023
Q3 		$1.66K Buy
34
+3
+10% +$204 ﹤0.01% 2354
2023
Q2 		$2.41K Sell
31
-139
-82% -$13.2K ﹤0.01% 2358
2023
Q1 		$15K Hold
170
– – ﹤0.01% 2085
2022
Q4 		$20K Sell
170
-57
-25% -$9.67K ﹤0.01% 2064
2022
Q3 		$37K Buy
227
+57
+34% +$8.88K ﹤0.01% 1857
2022
Q2 		$15K Buy
170
+139
+448% +$14.6K ﹤0.01% 2120
2022
Q1 		$5K Buy
+31
New +$6.18K ﹤0.01% 2314
2021
Q4 		– Sell
-196
Closed -$113 – 2332
2021
Q3 		$113 Buy
196
+153
+356% +$70.9K ﹤0.01% 1643
2021
Q2 		$20 Buy
+43
New +$22.2K ﹤0.01% 2139

Other funds holding KLRS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nisa Investment Advisors's KLRS Position: Q4 2024 in Review

Nisa Investment Advisors held its Kalaris Therapeutics (KLRS) position steady in Q4 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3065.

Nisa Investment Advisors first reported a position in KLRS in Q2 2021 and has held it in 10 quarters since. The position peaked at $37K in Q3 2022. 52 funds tracked by Wall St. Rank hold KLRS as of Q4 2024.

  • Nisa Investment Advisors held 0 shares of Kalaris Therapeutics worth $0 as of Q4 2024.
  • Nisa Investment Advisors left its Kalaris Therapeutics share count unchanged in Q4 2024.
  • Kalaris Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q4 2024, its #3065 holding.
  • Nisa Investment Advisors first reported a position in Kalaris Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • Nisa Investment Advisors's Kalaris Therapeutics position peaked at $37K in Q3 2022.
  • 52 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2024.

Based on Nisa Investment Advisors's 13F filing for Q4 2024, filed 17 Jan 2025.